ArticleJMA journal2026

Editorial Comment to Immune Checkpoint Inhibitor Retreatment after Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Descriptive Study with Exploratory Evaluation of Radiotherapy.

Jimpei MiyakawaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.